In situ implantable DNA hydrogel for diagnosis and therapy of postoperative rehemorrhage following intracerebral hemorrhage surgery
Science Advances · 2024
DOI: 10.1126/sciadv.ado3919 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Wenyan Yu und 18 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China. Hauptthemen laut MEDLINE: Cerebral Hemorrhage, Hydrogels, Hemoglobins. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Postoperative rehemorrhage following intracerebral hemorrhage surgery is intricately associated with a high mortality rate, yet there is now no effective clinical treatment. In this study, we developed a hemoglobin (Hb)–responsive in situ implantable DNA hydrogel comprising Hb aptamers cross-linked with two complementary chains and encapsulating deferoxamine mesylate (DFO). Functionally, the hydrogel generates signals upon postoperative rehemorrhage by capturing Hb, demonstrating a distinctive “self-diagnosis” capability. In addition, the ongoing capture of Hb mediates the gradual disintegration of the hydrogel, enabling the on-demand release of DFO without compromising physiological iron-dependent functions. This process achieves self-treatment by inhibiting the ferroptosis of neurocytes. In a collagenase and autologous blood injection model–induced mimic postoperative rehemorrhage model, the hydrogel exhibited a 5.58-fold increase in iron absorption efficiency, reducing hematoma size significantly (from 8.674 to 4.768 cubic millimeters). This innovative Hb-responsive DNA hydrogel not only offers a therapeutic intervention for postoperative rehemorrhage but also provides self-diagnosis feedback, holding notable promise for enhancing clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
- Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases, Zhengzhou 450001, China.
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou 450001, China.
ORCID-Profile: Zhenya Wang, Zhenzhong Zhang, Kaixiang Zhang, Junjie Liu, Jinjin Shi
Zitieren
APA
Yu, W., Gong, E., Wang, C., Che, C., Zhao, Y., Wu, X., Yang, Y., Shi, H., Chen, M., Li, M., Xie, L., Guo, Y., Guo, M., Mu, L., Wang, Z., Zhang, Z., Zhang, K., Liu, J., & Shi, J. (2024). In situ implantable DNA hydrogel for diagnosis and therapy of postoperative rehemorrhage following intracerebral hemorrhage surgery. Science Advances. https://doi.org/10.1126/sciadv.ado3919
Vancouver
Yu W, Gong E, Wang C, Che C, Zhao Y, Wu X, et al. In situ implantable DNA hydrogel for diagnosis and therapy of postoperative rehemorrhage following intracerebral hemorrhage surgery. Science Advances. 2024. doi:10.1126/sciadv.ado3919
BibTeX
@article{Yu2024,
author = {Yu, Wenyan and Gong, Enpeng and Wang, Changlin and Che, Chengyuan and Zhao, Yuzhen and Wu, Xinyun and Yang, Yi and Shi, Haiyu and Chen, Mengjuan and Li, Mingge and Xie, Li and Guo, Yue and Guo, Mingming and Mu, Liya and Wang, Zhenya and Zhang, Zhenzhong and Zhang, Kaixiang and Liu, Junjie and Shi, Jinjin},
title = {In situ implantable DNA hydrogel for diagnosis and therapy of postoperative rehemorrhage following intracerebral hemorrhage surgery},
journal = {Science Advances},
year = {2024},
doi = {10.1126/sciadv.ado3919}
}
EUVIMED